4-((1H-Imidazol-2-yl)methylene)-3-methyl-1(4-phenylthiazol-2-yl)-1H-pyrazol-5(4H)-one

ID: ALA3417399

PubChem CID: 90478320

Max Phase: Preclinical

Molecular Formula: C17H13N5OS

Molecular Weight: 335.39

Molecule Type: Small molecule

Names and Identifiers

Canonical SMILES:  CC1=NN(c2nc(-c3ccccc3)cs2)C(=O)/C1=C/c1ncc[nH]1

Standard InChI:  InChI=1S/C17H13N5OS/c1-11-13(9-15-18-7-8-19-15)16(23)22(21-11)17-20-14(10-24-17)12-5-3-2-4-6-12/h2-10H,1H3,(H,18,19)/b13-9+

Standard InChI Key:  REIKSWQMCGHUHP-UKTHLTGXSA-N

Molfile:  

     RDKit          2D

 24 27  0  0  0  0  0  0  0  0999 V2000
   13.7274   -1.3002    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   12.8113   -2.4879    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   11.4166   -1.9714    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   11.4416   -0.4843    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   12.8808   -0.0619    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   10.1759   -2.8158    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.7343   -2.9815    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.2010   -3.2956    0.0000 S   0  0  0  0  0  0  0  0  0  0  0  0
    4.9531   -1.9978    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.9511   -0.8815    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    2.5987   -1.5004    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.4458   -1.8433    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    7.0687   -0.4917    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    8.5555   -0.6902    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.8261   -2.1656    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.5066   -2.8789    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.3405   -4.0673    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    1.2990   -0.7500    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.2990    0.7500    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    1.5000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.2990    0.7500    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.2990   -0.7500    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000   -1.5000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.3831    0.1788    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  1  0
  3  4  2  0
  4  5  1  0
  5  1  2  0
  3  6  1  0
  7  8  1  0
  8  9  1  0
  9 10  2  0
 10 11  1  0
 11  7  2  0
  9 12  1  0
 12 13  1  0
 13 14  2  0
 14 15  1  0
 15 16  1  0
 16 12  1  0
 16 17  2  0
 15  6  2  0
 18 19  2  0
 19 20  1  0
 20 21  2  0
 21 22  1  0
 22 23  2  0
 23 18  1  0
 11 18  1  0
 14 24  1  0
M  END

Alternative Forms

1. Parent:

   

   ALA3417399

   4-((1H-imidazol-2-yl)methylene)-5-methyl-2-(4-phenylthiazol-2-yl)-2,4-dihydro-3H-pyrazol-3-one

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 335.39

Molecular Weight (Monoisotopic): 335.0841

AlogP: 3.34

#Rotatable Bonds: 3

Polar Surface Area: 74.24

Molecular Species: NEUTRAL

HBA: 5

HBD: 1

#RO5 Violations: ┄

HBA (Lipinski): 6

HBD (Lipinski): 1

#RO5 Violations (Lipinski): ┄

CX Acidic pKa: 12.51

CX Basic pKa: 6.30

CX LogP: 3.06

CX LogD: 3.03

Aromatic Rings: 3

Heavy Atoms: 24

QED Weighted: 0.75

Np Likeness Score: -1.80

References

1. Stornaiuolo M, La Regina G, Passacantilli S, Grassia G, Coluccia A, La Pietra V, Giustiniano M, Cassese H, Di Maro S, Brancaccio D, Taliani S, Ialenti A, Silvestri R, Martini C, Novellino E, Marinelli L..  (2015)  Structure-based lead optimization and biological evaluation of BAX direct activators as novel potential anticancer agents.,  58  (5): [PMID:25668341] [10.1021/jm501123r]

Source

Source(1):

• Scientific Literature